Why AngioDynamics Crashed Today
AngioDynamics (ANGO) shares fell 20.7% despite beating Q1 earnings estimates. The company reported a $0.04 per share pro forma loss, but a $0.17 GAAP loss. Revenue grew 6.9% year-over-year. Eric Honroth was named CEO, succeeding Jim Clemmer. The company has not been profitable since 2020 and is not expected to be until 2029, according to analysts.
How this was made
The 30-second read
Why it matters
The earnings miss and weak guidance triggered a 20.7% drop, suggesting heightened risk for short positions.
Market read
First‑report earnings disclosure with a sizable intraday move; relevant for short‑term traders in healthcare small caps.
What to watch
Potential upside from upcoming product launches or regulatory approvals not covered in the earnings release.
Background
AngioDynamics (NASDAQ:ANGO) is a medical‑device maker known for the NanoKnife cancer‑treatment system.
Ticker impact
AngioDynamics reported Q1 2027 earnings with a pro‑forma loss of $0.04 per share (GAAP loss $0.17) and guidance for lower sales, causing the stock to tumble 20.7% intraday.
likely pressure as the market prices in the GAAP loss and lower‑than‑expected sales guidance
The earnings beat was only pro‑forma, GAAP loss widened, and guidance signals continued losses through 2029, prompting a sharp sell‑off.
Market effects
Highlights weakness in the medical‑device sector, especially companies reliant on peripheral vascular and oncology tools.
U.S. small‑cap healthcare stocks may see modest pullback.
Limited to investors tracking U.S. med‑tech earnings; no broader macro effect.
Counterpoint
If the market overreacts to the GAAP loss, a bounce could occur on the debt‑free balance sheet and cash position.
Key entities
- personEric Honroth
New CEO, previously Global President of Life Science at Getinge.
